Cost-Effectiveness Analysis of the Implementation of Single-Dose Vitamin D, Omega 3, or Co-Supplementation on Individuals with PCOS
Author(s)
Olin S1, Shi L2, Park S3, Xuan D2
1Tulane University, New Orleans, LA, USA, 2Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Presentation Documents
OBJECTIVES: This study assesses the cost-effectiveness of vitamin D and Omega-3 supplements on HbA1C levels to reduce prediabetes and diabetes risks in PCOS-diagnosed females.
METHODS: A simple Markov model simulated a PCOS (Polycystic Ovary Syndrome) population for seven total 8-week cycles including the following states based on HbA1C levels: normal glucose tolerance, prediabetic, and type 2 diabetic. Costs were analyzed in 2023 US dollars from a healthcare and societal perspective using estimates with an annual discount rate of 3%. Individuals could transition bidirectionally between states, with death as the final state. Transition states were estimated from previous studies and weights were applied for each treatment group. With 5% effectiveness applied for single dose of both vitamin D and Omega 3 and 10% effectiveness applied to co-supplementation. Quality-adjusted life years were pulled from previous work which applied a calculation based on SF-12 scores and a willingness-to-pay threshold of $100,000 was applied to the model.
RESULTS: Base case analysis results showed that vitamin D and co-supplementation were dominant strategies when applied to a comprehensive perspective including both healthcare and societal costs. Vitamin D had the lowest treatment cost for the 56 weeks when compared to all other treatment groups with a total cost of $357.39. However, base case analysis resulted in incremental cost effectiveness ratios less than or equal to zero for both no treatment and Omega-3 (No Treatment: -279529.75; Omega 3: 0.00). Effectiveness results showed all treatment options having an effectiveness of 0.76 QALY, with all groups have a 0.00 incremental effectiveness when compared to Vitamin D. A probabilistic sensitivity analysis indicates no treatment as optimal in 97.30% of 1,000 simulations.
CONCLUSIONS: Vitamin D and co-supplementation were dominant strategies compared to no treatment and Omega 3. When a $100,000 WTP threshold was used, all treatments yielded positive net monetary benefits, compared with Vitamin D.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 6, S1 (June 2024)
Code
EE294
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas